Procter & Gamble Health Surpasses Expectations with 30% Net Profit Growth
Procter & Gamble Health (P&G Health) delivered strong financial results for FY26, driven by increased sales and productivity savings. The company's net profit rose 30% year-over-year, while sales grew 16%. A key contributor to this growth was the implementation of productivity initiatives, which yielded ₹35 crore in cost savings.
The shift to a new fiscal calendar, with FY26 covering April 1, 2025, to March 31, 2026, allowed for more accurate year-over-year comparisons. This change was made to improve comparability and provide a clearer picture of the company's financial performance.
Management emphasized an integrated growth strategy centered on portfolio performance and consumer superiority. Key product categories driving momentum include Neurobion, Livogen, Evion, and Nasivion. The company also highlighted packaging innovations designed to educate consumers and improve shelf visibility.